372 related articles for article (PubMed ID: 28657143)
1. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
3. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
6. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Fujisaki K; Hashiguchi M; Inada Y; Uto H; Hiramine Y; Kure T; Hori T; Taniyama O; Kasai A; Tamai T; Moriuchi A; Ido A
PLoS One; 2018; 13(6):e0198642. PubMed ID: 29856885
[TBL] [Abstract][Full Text] [Related]
7. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
[TBL] [Abstract][Full Text] [Related]
9. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
12. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Zhang X; Setze C; Rodrigues L; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2016 Feb; 60(2):1106-13. PubMed ID: 26643326
[TBL] [Abstract][Full Text] [Related]
16. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Feld JJ; Ramji A; Shafran SD; Willems B; Marotta P; Huchet E; Vachon ML; Svarovskaia ES; Huang KC; Hyland RH; Yun C; Massetto B; Brainard DM; McHutchison JG; Tam E; Bailey R; Cooper C; Yoshida EM; Greenbloom S; Elkhashab M; Borgia S; Swain MG
Clin Infect Dis; 2017 Jul; 65(1):13-19. PubMed ID: 28535298
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]